SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JS Ogrady who wrote (125)8/22/1998 11:18:00 AM
From: Bioscoop   of 416
 
How much more use will the new vaccine, Synagis get compared to Respigam due to its easier smaller dose, intramuscular formulation vs i.v in the scalp. The efficacy doesn't appear to be any better as a randomized study hasnt' been done.

In what patient population has Respigam been used historically and in which population do you see Synagis being expanded into this winter?

Thank you for your time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News